Natera Q2 revenue $752.8M (+37.7% YoY); raises FY2026 guidance by $100M

Natera, Inc.

Revenue $752.8M (+37.7% YoY); tests processed 1,043,900 (+22.4%); oncology tests 296,700 (+57.2%).
Net loss $67.0M ($0.47 diluted EPS) vs $100.9M ($0.74) in Q2 2025; operating loss $75.8M vs $110.4M.
Raised 2026 annual revenue guidance by $100M midpoint to $2.85B-$2.91B; gross margin ~64-66%.
Cash increased $3.6M in Q2 to $1,091.5M; debt $80.3M under UBS line at SOFR+50bps.
CEO cites Signatera regulatory approvals, Medicare coverage for Prospera, and Panorama NIPT launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.